Scanlon KJ - Search Results

1

Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O. Maelandsmo GM, et al. Among authors: scanlon kj. Cancer Res. 1996 Dec 1;56(23):5490-8. Cancer Res. 1996. PMID: 8968106

2

Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.

Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Kashani-Sabet M, et al. Among authors: scanlon kj. Cancer Res. 1994 Feb 15;54(4):900-2. Cancer Res. 1994. PMID: 8313379

3

Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.

Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm PS, Curiel DT, Kashani-Sabet M, Scanlon KJ. Suzuki T, et al. Among authors: scanlon kj. Gene Ther. 2000 Feb;7(3):241-8. doi: 10.1038/sj.gt.3301065. Gene Ther. 2000. PMID: 10694801

4

Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.

Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT. Feng M, et al. Among authors: scanlon kj. Cancer Res. 1995 May 15;55(10):2024-8. Cancer Res. 1995. PMID: 7743496

5

Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.

Funato T, Ishii T, Kambe M, Scanlon KJ, Sasaki T. Funato T, et al. Among authors: scanlon kj. Cancer Gene Ther. 2000 Mar;7(3):495-500. doi: 10.1038/sj.cgt.7700125. Cancer Gene Ther. 2000. PMID: 10766356

6

Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.

Ohta Y, Kijima H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Ohta Y, et al. Among authors: scanlon kj. Nucleic Acids Res. 1996 Mar 1;24(5):938-42. doi: 10.1093/nar/24.5.938. Nucleic Acids Res. 1996. PMID: 8600463 Free PMC article.

7

Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins.

Iida T, Kijima H, Urata Y, Goto S, Ihara Y, Oka M, Kohno S, Scanlon KJ, Kondo T. Iida T, et al. Among authors: scanlon kj. Cancer Gene Ther. 2001 Oct;8(10):803-14. doi: 10.1038/sj.cgt.7700371. Cancer Gene Ther. 2001. PMID: 11687904

8

Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.

Funato T, Ishii T, Kanbe M, Scanlon KJ, Sasaki T. Funato T, et al. Among authors: scanlon kj. In Vivo. 1997 May-Jun;11(3):217-20. In Vivo. 1997. PMID: 9239514

9

Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.

Holm PS, Scanlon KJ, Dietel M. Holm PS, et al. Among authors: scanlon kj. Br J Cancer. 1994 Aug;70(2):239-43. doi: 10.1038/bjc.1994.286. Br J Cancer. 1994. PMID: 7914421 Free PMC article.

10

mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.

Daly C, Coyle S, McBride S, O'Driscoll L, Daly N, Scanlon K, Clynes M. Daly C, et al. Cytotechnology. 1996;19(3):199-205. doi: 10.1007/BF00744213. Cytotechnology. 1996. PMID: 8862007

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters